Please ensure Javascript is enabled for purposes of website accessibility

Why Editas Medicine Stock Sank Today

By Keith Speights - Mar 4, 2021 at 4:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock was pulled down by the undertow of the broader market sell-off.

What happened

Shares of Editas Medicine (EDIT 4.40%) were down 6.8% as of 3:51 p.m. EST on Thursday. The company didn't report any news that would cause its stock to fall. Instead, Editas' decline resulted from the overall stock market sell-off.

So what

Clinical-stage biotech stocks tend to be a lot more volatile than the major benchmark indexes. When the market drops, these stocks often fall even harder.

What should investors do? Sit tight. Market swings come and they go. The important thing to focus on is Editas' prospects for its gene-editing therapies in development.

Multiple DNA double helixes with a healthcare professional in the background

Image source: Getty Images.

The biotech has two clinical studies moving forward. Editas is dosing patients in its early-stage study evaluating EDIT-101 in treating rare genetic eye disease Leber congenital amaurosis type 10 (LCA10). It has also initiated a phase 1/2 study evaluating EDIT-301 in treating sickle cell disease.

Now what

The major milestone to watch for with Editas will be the initial results from its study of EDIT-101. The company expects to report those results later this year. Editas also hopes to file by the end of the year for U.S. Food and Drug Administration (FDA) approval to begin a study of EDIT-301 in treating rare blood disorder beta-thalassemia.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
EDIT
$11.63 (4.40%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.